MARC Record from marc_columbia

LEADER: 05331cam a2200673 i 4500
001 15129621
005 20220219230632.0
006 m o d
007 cr cnu|||unuuu
008 180125r20181995flu ob 001 0 eng d
035 $a(OCoLC)on1020319025
035 $a(NNC)15129621
040 $aN$T$beng$erda$epn$cN$T$dEBLCP$dN$T$dYDX$dNLE$dOCLCF$dCUS$dUKMGB$dUWO$dAU@$dOCLCQ$dOCLCO$dOCLCQ
015 $aGBB842019$2bnb
016 7 $a018753495$2Uk
019 $a1020622605
020 $a9781351070409$q(electronic bk.)
020 $a1351070401$q(electronic bk.)
020 $a1351087304
020 $a9781351087308
020 $a9781351078856
020 $a1351078852
020 $z9781315891309
035 $a(OCoLC)1020319025$z(OCoLC)1020622605
037 $a9781351087308$bIngram Content Group
050 4 $aRC271.R26
072 7 $aHEA$x039000$2bisacsh
072 7 $aMED$x014000$2bisacsh
072 7 $aMED$x022000$2bisacsh
072 7 $aMED$x112000$2bisacsh
072 7 $aMED$x045000$2bisacsh
082 04 $a616.99/40642$223
049 $aZCUA
245 00 $aCancer therapy with radiolabeled antibodies /$cedited by David M. Goldenberg.
264 1 $aRoca Raton, FL :$bCRC Press, Taylor & Francis Group,$c2018.
300 $a1 online resource
336 $atext$btxt$2rdacontent
337 $acomputer$bc$2rdamedia
338 $aonline resource$bcr$2rdacarrier
490 1 $aCRC revivals
500 $aOriginally published 1995 by CRC Press.
505 0 $aCover; Title Page; Copyright Page; Dedication; Table of Contents; Chapter 1 Introduction; RADIOBIOLOGY, RADIATION PHYSICS, AND DOSIMETRY; Chapter 2 Medical Internal Dosimetry for High-Dose Radionuclide Therapies; Chapter 3 Radiolabeled Antibody Tumor Dosimetry; Chapter 4 Radiobiology and Radioimmunotherapy: Implications for Clinical Applications; RADIOCHEMISTRY OF THERAPEUTIC RADIONUCLIDES; Chapter 5 Radiochemistry of Therapeutic Radionuclides; Chapter 6 Advanced Methods for Radiolabeling Monoclonal Antibodies with Therapeutic Radionuclides
505 8 $aChapter 7 Antibody Radiolabeling with Isotopes of RheniumTARGETING, PHARMACOKINETICS, AND EXPERIMENTAL RADIOIMMUNOTHERAPY; Chapter 8 Pharmacokinetics of Antibodies and their Radiolabels; Chapter 9 Development of Cancer Radioimmunotherapy and its Potential Use as an Adjuvant Treatment; Chapter 10 Experimental Radioimmunotherapy and Methods to Increase Therapeutic Efficacy; CLINICAL RADIOIMMUNOTHERAPY; Chapter 11 Overview of Obstacles and Opportunities for Radioimmunotherapy of Cancer; Chapter 12 Radioimmunotherapy of Ovarian Cancer; Chapter 13 Radioimmunotherapy of Colorectal Cancer
505 8 $aChapter 14 Radioimmunotherapy in the Treatment of Metastatic Breast Cancer: An OverviewChapter 15 Radioimmunotherapy of CNS Malignant Gliomas by Direct Intralesional Injection of Specific 131I Radiolabeled Monoclonal Antibodies; Chapter 16 Treatment of B-Lymphocyte Malignancies with 131I-Lym-l-and 67Cu-2IT-BAT-Lym-l and Opportunities for Improvement; Chapter 17 Treatment of Relapsed B Cell Lymphomas with High-Dose Radioimmunotherapy and Bone Marrow Transplantation; NEW STRATEGIES; Chapter 18 Clinical Application of the Avidin-Biotin System for Tumor Targeting
505 8 $aChapter 19 Humanization of Monoclonal Antibodies: Molecular Approaches and ApplicationsChapter 20 Human Monoclonal Antibodies: Application in Radioimmunotherapy; Chapter 21 Cytokine-Based Modalities to Enhance Monoclonal-Antibody-Mediated Tumor Cell Killing; Chapter 22 Overcoming Dose-Limiting, Antibody-Induced Myelotoxicity; Index
504 $aIncludes bibliographical references and index.
520 $a"Cancer Therapy with Radiolabeled Antibodies explores the most current experimental and clinical advances in the newly emerging field of cancer radioimmunotherapy (RAIT). Providing a multidisciplinary and international context, some of the world's leading experts examine the problems and prospects of RAIT from radiation, immunological, chemical, physical, physiological, and clinical perspectives with both overviews and original research. Discussions cover the up-to-date clinical results in the RAIT of ovarian, breast, colorectal, and brain cancers, as well as the current status of RAIT in the management of B cell lymphomas. Radiobiology, dosimetry, radiochemistry, targeting biology in experimental models, clinical experiences in hematopoietic and solid tumors, and new approaches to improve cancer radioimmunotherapy are also discussed. In addition, new dosimetry concepts, new labeling methods, new concepts of antibody pharmacokinetics, and new methods to enhance selective cancer radioimmunotherapy are included."--Provided by publisher
650 0 $aCancer$xRadioimmunotherapy.
650 7 $aHEALTH & FITNESS$xDiseases$xGeneral.$2bisacsh
650 7 $aMEDICAL$xClinical Medicine.$2bisacsh
650 7 $aMEDICAL$xDiseases.$2bisacsh
650 7 $aMEDICAL$xEvidence-Based Medicine.$2bisacsh
650 7 $aMEDICAL$xInternal Medicine.$2bisacsh
650 7 $aCancer$xRadioimmunotherapy.$2fast$0(OCoLC)fst00845471
655 4 $aElectronic books.
700 1 $aGoldenberg, David M.,$d1938-$eeditor.
830 0 $aCRC revivals.
856 40 $uhttp://www.columbia.edu/cgi-bin/cul/resolve?clio15129621$zTaylor & Francis eBooks
852 8 $blweb$hEBOOKS